To examine how fusion protein-based costimulatory strategies can enhance T cell function and remodel the tumor microenvironment in adoptive T cell therapies, particularly addressing challenges in solid tumors.
Approach:
Key Findings:
Fusion protein-based costimulatory strategies can enhance T cell function, leading to improved therapeutic outcomes.
These strategies can remodel the tumor microenvironment, making previously resistant tumors more responsive to treatment.
Conventional and non-canonical costimulatory modules can be integrated into T cell therapies, expanding their applicability.
Interpretation:
The advancements in fusion protein-based strategies provide a framework for enhancing the therapeutic potential of adoptive T cell therapies in solid tumors.
Limitations:
The review does not address specific clinical trial data for the discussed strategies, which limits understanding of their real-world applicability.
Potential toxicity and safety concerns associated with engineered T cells are not extensively covered, raising questions about their clinical use.
Conclusion:
Fusion protein-based receptors and ligands represent a promising approach to enhance T cell therapy efficacy in solid tumors.
